RA, reuma, Rheumatoid Arthritis
Conditions
Interventions
We want to study otherwise healthy volunteers undergoing new influenza A/H1N1 infection.
We will combine in-vitro stimulation assays and High Throughput Sequencing to identify, quantify and phenotype
Sponsors
Academisch Medisch Centrum, div Immunology and Rheumatology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Able and willing to give written informed consent; 2. Age 18-85 years; 3. PCR-confirmed new influenza A/H1N1 infection with symptoms present for less than 4 days.
Exclusion criteria
Exclusion criteria: 1. Therapy within the previous 60 days with: A. Any experimental drug; B. Monoclonal antibodies; C. Growth factors; D. Other anti-cytokines. 2. Therapy within the previous 28 days with: A. Anti-viral medication; B. Parenteral corticoid injections; C. Oral corticosteroid therapy exceeding a prednisone equivalent of 10 mg daily. 3. Any clinically significant medical condition; 4. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Frequency of in-vitro responding clones during follow-up of the new influenza A/H1N1 virus infection; 2. Functional characterization of individual responding clones; 3. Correlation of T-cell responses with antibody responses. | — |
Secondary
| Measure | Time frame |
|---|---|
| Antibody titers of 1:40 or more on hemagglutination-inhibition (HI) assay to quantify the presence of specific antigens. | — |
Contacts
Public ContactA.N. Scholten
Meibergdreef 9, F4-105
Outcome results
None listed